The sharp decline in collaboration revenue and resulting net loss are significant negative developments, despite positive clinical updates. Traders should monitor upcoming clinical data readouts in 2026 as key catalysts, but the financial deterioration suggests increased risk. The cash runway into Q3 2027 provides near-term stability, but future dilution risk may increase if revenue does not recover.
Price Chart
Executive Summary
Entrada Therapeutics reported financial results for Q4 and full year 2025, showing a significant decline in collaboration revenue and a shift from net income to a net loss compared to the prior year. The company highlighted clinical progress in its DMD and DM1 programs, including a positive DMC recommendation to advance the ELEVATE-44-201 study to a higher dose cohort. Cash runway is expected into Q3 2027 with $295.7 million in cash and marketable securities.
Key Financial Metrics
Key Facts
- Collaboration revenue dropped to $25.4 million in 2025 from $210.8 million in 2024, primarily due to the substantial completion of VX-670 collaboration research activities in Q1 2025.
- Net loss was $143.8 million for 2025 compared to net income of $65.6 million in 2024.
- Cash, cash equivalents, and marketable securities were $295.7 million as of December 31, 2025, down from $420.0 million as of December 31, 2024.
- The Independent Data Monitoring Committee recommended initiating Cohort 2 at a higher dose (12 mg/kg) in the ELEVATE-44-201 study without protocol modifications.
- The company expects to report data from ELEVATE-44-201 Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026.
Financial Impact
Revenue declined by $185.4 million YoY, resulting in a net loss of $143.8 million in 2025 versus net income of $65.6 million in 2024.
Risk Factors
- Significant decline in collaboration revenue with no indication of new major partnerships to replace VX-670 funding.
- Increased R&D and GA expenses are outpacing any new revenue streams, leading to substantial cash burn.
- Clinical trial timelines and outcomes remain uncertain, with no guarantee of regulatory approval even with positive data readouts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001689375-26-000009 |
| Document: trda-20260226.htm | 0001689375-26-000009 |
| Document: 0001689375-26-000009-index-headers.html | 0001689375-26-000009 |
| Document: 0001689375-26-000009-index.html | 0001689375-26-000009 |
| Document: 0001689375-26-000009.txt | 0001689375-26-000009 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | Insider Cluster | $6.42 $6.90 | ▼ −7.48% | ▼ −7.98% | $5.38 (+16.20%) |
Sep 3, 2026 29d ago | Insider Cluster | $7.17 $6.80 | ▼ −5.16% | ▼ −4.01% | $5.38 (−24.97%) |
Aug 31, 2026 4w ago | Insider Cluster | $7.07 $7.11 | ▲ +0.57% | ▲ +0.48% | $5.38 (−23.90%) |
Aug 31, 2026 4w ago | Insider Cluster | $7.07 $7.11 | ▲ +0.57% | ▲ +0.48% | $5.38 (−23.90%) |
Aug 31, 2026 4w ago | Insider Cluster | $7.07 $7.11 | ▲ +0.57% | ▲ +0.48% | $5.38 (−23.90%) |
Aug 27, 2026 5w ago | Insider Cluster | $7.27 $7.17 | ▼ −1.38% | ▼ −1.64% | $5.38 (−26.00%) |
Aug 10, 2026 7w ago | Insider Cluster | $7.04 $7.27 | ▲ +3.27% | ▲ +3.67% | $5.38 (−23.58%) |
Aug 5, 2026 8w ago | 8-K | $7.06 $7.67 | ▲ +8.64% | ▲ +8.29% | $5.38 (−23.80%) |
Aug 3, 2026 8w ago | Insider Cluster | $7.24 $7.04 | ▼ −2.76% | ▼ −2.66% | $5.38 (−25.69%) |
Jul 30, 2026 9w ago | 144 | $6.79 $6.87 | ▼ −1.18% | ▲ +2.33% | $5.38 (+20.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access